GENB Generate Biomedicines
Generate Biomedicines earnings company data as of 10:08 AM ET 10/30
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | -0.55 | — | — |
| Rev | $7.8M | — | — |
Insider trades
Open-market buys and sales by GENB's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $150M bought by 5 insiders
- None no sales outside a trading plan
- $16K sold by 1 insider under 10b5-1 plans
-
Frances Arnold DirectorPlanned sale$16K 1,000 shares at $16.00 0.4% of stakeTraded Sep 1 Filed Sep 3
-
Michael Nally CEOBuy$240K 20,000 shares at $12.00 +3.6% to stakeTraded Mar 4 Filed Mar 6
-
Beth Grous Chief People OfficerBuy$4,800 300 shares at $16.00 New stakeTraded Mar 2 Filed Mar 2
-
Jason Silvers CFOBuy$32K 2,000 shares at $16.00 New stakeTraded Mar 2 Filed Mar 2
-
Noubar Afeyan Director, +7 joint filersBuy$75M 4,687,500 shares at $16.00 New stakeTraded Mar 2 Filed Mar 2
-
Jane L Mendillo DirectorBuy$24K 1,500 shares at $16.00 New stakeTraded Mar 2 Filed Mar 2
Also filed in the last 12 months, not counted as buying or selling: 12 conversions.
SEC filings
Recent issuer filings from EDGAR, 12 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.03,9.01 | Filing Doc | |
| 424B4 | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.